Kawada T, Mizuno M, Shimizu S, Uemura K, Kamiya A, Sugimachi M. Angiotensin II disproportionally attenuates dynamic vagal and sympathetic heart rate controls. Am J Physiol Heart Circ Physiol 296: H1666 -H1674, 2009. First published February 27, 2009 doi:10.1152/ajpheart.01041.2008.-To better understand the pathophysiological role of angiotensin II (ANG II) in the dynamic autonomic regulation of heart rate (HR), we examined the effects of intravenous administration of ANG II (10 g ⅐ kg Ϫ1 ⅐ h Ϫ1 ) on the transfer function from vagal or sympathetic nerve stimulation to HR in anesthetized rabbits with sinoaortic denervation and vagotomy. In the vagal stimulation group (n ϭ 7), we stimulated the right vagal nerve for 10 min using binary white noise (0 -10 Hz). The transfer function from vagal stimulation to HR approximated a first-order low-pass filter with pure delay. ANG II attenuated the dynamic gain from 7.6 Ϯ 0.9 to 5.8 Ϯ 0.9 beats ⅐ min Ϫ1 ⅐ Hz Ϫ1 (means Ϯ SD; P Ͻ 0.01) without affecting the corner frequency or pure delay. In the sympathetic stimulation group (n ϭ 7), we stimulated the right postganglionic cardiac sympathetic nerve for 20 min using binary white noise (0 -5 Hz). The transfer function from sympathetic stimulation to HR approximated a second-order low-pass filter with pure delay. ANG II slightly attenuated the dynamic gain from 10.8 Ϯ 2.6 to 10.2 Ϯ 3.1 beats ⅐ min Ϫ1 ⅐ Hz Ϫ1 (P ϭ 0.049) without affecting the natural frequency, damping ratio, or pure delay. The disproportional suppression of the dynamic vagal and sympathetic regulation of HR would result in a relative sympathetic predominance in the presence of ANG II. The reduced high-frequency component of HR variability in patients with cardiovascular diseases, such as myocardial infarction and heart failure, may be explained in part by the peripheral effects of ANG II on the dynamic autonomic regulation of HR. systems analysis; transfer function; heart rate variability; cardiac sympathetic nerve activity; rabbit AUTONOMIC NERVOUS ACTIVITY changes dynamically during daily activity, and thus the dynamic heart rate (HR) regulation by the autonomic nervous system is physiologically important. The high-frequency (HF) component of HR variability (HRV) is thought to reflect primarily vagal nerve activity, because the vagal nerve can change the HR more quickly than the sympathetic nerve (1, 3, 14, 34 ). This does not mean, however, that the sympathetic system cannot affect the HF component. For example, an increase in background sympathetic tone augments the HR response to vagal stimulation, an effect that has been referred to as accentuated antagonism (20) . In accordance with accentuated antagonism, selective cardiac sympathetic nerve stimulation augments the dynamic HR response to vagal stimulation (14). On the other hand, high plasma concentration of norepinephrine (NE) with no direct activation of the cardiac sympathetic nerve attenuates the dynamic HR response to vagal stimulation via an ␣-adrenergic mechanism (24). These results suggest that the sympathetic system can influence the HF component via complex interactions with the vagal system.
AUTONOMIC NERVOUS ACTIVITY changes dynamically during daily activity, and thus the dynamic heart rate (HR) regulation by the autonomic nervous system is physiologically important. The high-frequency (HF) component of HR variability (HRV) is thought to reflect primarily vagal nerve activity, because the vagal nerve can change the HR more quickly than the sympathetic nerve (1, 3, 14, 34) . This does not mean, however, that the sympathetic system cannot affect the HF component. For example, an increase in background sympathetic tone augments the HR response to vagal stimulation, an effect that has been referred to as accentuated antagonism (20) . In accordance with accentuated antagonism, selective cardiac sympathetic nerve stimulation augments the dynamic HR response to vagal stimulation (14) . On the other hand, high plasma concentration of norepinephrine (NE) with no direct activation of the cardiac sympathetic nerve attenuates the dynamic HR response to vagal stimulation via an ␣-adrenergic mechanism (24) . These results suggest that the sympathetic system can influence the HF component via complex interactions with the vagal system.
During systemic sympathetic activation, the renin-angiotensin system is activated through stimulation of ␤ 1 -adrenergic receptors on juxtaglomerular granular cells (8, 12) . In such conditions as hypertension, myocardial ischemia, and heart failure, the renin-angiotensin system and the sympathetic nervous system are both activated (9, 35) . Previous studies demonstrated that acute intravenous or intracerebroventricular administration (32) or chronic intravenous administration of angiotensin II (ANG II) modified the baroreflex control of HR in rabbits (5) , possibly via a decrease in vagal tone and an increase in sympathetic tone to the heart. In the present study, we focused on the peripheral effects of ANG II and examined the effects of intravenous ANG II on the dynamic HR response to vagal or postganglionic cardiac sympathetic nerve stimulation. In a previous study from our laboratory where anesthetized cats were used, intravenous ANG II (10 g⅐kg Ϫ1 ⅐h Ϫ1 ) attenuated myocardial interstitial acetylcholine (ACh) release in response to vagal nerve stimulation (17) ; therefore, we hypothesized that intravenous ANG II at this dose would attenuate the dynamic HR response to vagal nerve stimulation. On the other hand, a previous study from our laboratory where anesthetized rabbits were used demonstrated that intravenous ANG II at a similar dose of 6 g⅐kg Ϫ1 ⅐h
Ϫ1
did not affect the peripheral arc transfer function estimated between renal sympathetic nerve activity and arterial pressure (AP) (13) . Accordingly, we hypothesized that intravenous administration of ANG II would not modulate the dynamic sympathetic control of HR significantly. We focused on the relative effects of ANG II on the vagal and sympathetic HR regulations because the balance between vagal and sympathetic nerve activities would be a key to understanding the pathophysiology of several cardiovascular diseases.
MATERIALS AND METHODS

Surgical preparations. Animal care was performed in accordance with Guideline Principles for the Care and Use of Animals in the Field
of Physiological Sciences, which has been approved by the Physiological Society of Japan. All experimental protocols were reviewed and approved by the Animal Subjects Committee at the National Cardiovascular Center. Twenty-one Japanese white rabbits weighing 2.4 -3.4 kg were anesthetized with intravenous injections (2 ml/kg) of a mixture of urethane (250 mg/ml) and ␣-chloralose (40 mg/ml) and mechanically ventilated with oxygen-enriched room air. A doublelumen catheter was inserted into the right femoral vein, and a supplemental dose of the anesthetics was given continuously (0.5-1.0 ml ⅐ kg Ϫ1 ⅐ h Ϫ1 ). AP was monitored using a micromanometer catheter (Millar Instruments, Houston, TX) inserted into the right femoral artery. HR was determined from the electrocardiogram using a cardiotachometer. Sinoaortic denervation and vagotomy were performed bilaterally to minimize reflex changes in efferent sympathetic nerve activity. The left and right cardiac sympathetic nerves were exposed using a midline thoracotomy and sectioned (16) . In the vagal stimulation group, a pair of bipolar stainless steel wire electrodes was attached to the cardiac end of the sectioned right vagal nerve for stimulation. A pair of stainless steel wire electrodes was attached to the proximal end of the sectioned right cardiac sympathetic nerve for recording efferent cardiac sympathetic nerve activity (CSNA). In the sympathetic stimulation group, a pair of bipolar stainless steel wire electrodes was attached to the cardiac end of the sectioned right sympathetic nerve for stimulation. Efferent CSNA was recorded from the proximal end of the sectioned left cardiac sympathetic nerve. The preamplified nerve signal was band-pass filtered between 150 and 1,000 Hz. The signal was then full-wave rectified and low-pass filtered with a cut-off frequency of 30 Hz to quantify the nerve activity. Both the stimulation and recording electrodes were fixed to the nerve by addition-curing silicone glue (Kwik-Sil; World Precision Instruments, Sarasota, FL). We confirmed that the recorded CSNA was mainly postganglionic by observing the disappearance of CSNA following intravenous administration of hexamethonium bromide (50 mg/kg) at the end of each experiment. The body temperature of the animal was maintained at 38°C with a heating pad throughout the experiment.
Protocols. In the vagal stimulation group (n ϭ 7), the stimulation amplitude was adjusted (3-6 V) in each animal to yield a HR decrease of ϳ50 beats/min at 5-Hz tonic stimulation with a pulse duration of 2 ms. To estimate the transfer function from vagal stimulation to HR, a random vagal stimulus was applied for 10 min by altering the stimulus command every 500 ms at either 0 or 10 Hz according to a binary white noise signal. The input power spectral density was relatively constant up to 1 Hz, which covered the upper frequency range of interest with respect to the vagal transfer function in rabbits (26) .
In the sympathetic stimulation group (n ϭ 7), the stimulation amplitude was adjusted (1-3 V) in each animal to yield a HR increase of ϳ50 beats/min at 5-Hz tonic stimulation with a pulse duration of 2 ms. To estimate the transfer function from sympathetic stimulation to HR, a random sympathetic stimulus was applied for 20 min by altering the stimulus command every 2 s at either 0 or 5 Hz according to a binary white noise signal. The input power spectral density was relatively constant up to 0.25 Hz, which covered the upper frequency range of interest with respect to the sympathetic transfer function in rabbits (15) .
In both the vagal stimulation and sympathetic stimulation groups, the dynamic HR response to nerve stimulation was first recorded under conditions of continuous intravenous infusion of physiological saline solution (1 ml ⅐ kg Ϫ1 ⅐ h Ϫ1 ). After the control data were recorded, nerve stimulation was stopped and ANG II was intravenously administered at 10 g ⅐ kg Ϫ1 ⅐ h Ϫ1 (1 ml ⅐ kg Ϫ1 ⅐ h Ϫ1 of 10 g/ml solution) instead of the physiological saline solution. After 15 min, we repeated the random stimulation of the vagal or sympathetic nerve while continuing the intravenous injection of ANG II. We used the same binary white noise sequence for the control and ANG II conditions in each animal and changed the sequence for different animals.
In a supplemental protocol (n ϭ 7), we examined the time effect on the estimation of the sympathetic transfer function. The 20-min random sympathetic stimulation was repeated twice with an intervening interval of more than 20 min.
Data analysis. Data were digitized at 200 Hz using a 16-bit analog-to-digital converter and stored on the hard disk of a dedicated laboratory computer system. Prestimulation values of HR, AP, and CSNA were calculated by averaging data obtained during the 10 s immediately before nerve stimulation. The mean HR and AP values in response to nerve stimulation were calculated by averaging data obtained during the nerve stimulation period. The mean level of CSNA during the nerve stimulation period was not evaluated because contamination from stimulation artifacts could not be completely eliminated.
The transfer function from nerve stimulation to the HR response was estimated as follows. The input-output data pairs of nerve stimulation and HR were resampled at 10 Hz. To avoid the initial transition from no stimulation to random stimulation biased the transfer function estimation, data were processed only from 2 min after the initiation of random stimulation. In the vagal stimulation group, the data were divided into eight segments of 1,024 data points that half-overlapped with neighboring segments. In the sympathetic stimulation group, the data were divided into eight segments of 2,048 data points that half-overlapped with neighboring segments. For each segment, a linear trend was subtracted and a Hanning window was applied. We then performed a fast Fourier transformation to obtain the frequency spectra of the stimulation command [X(f )] and HR [HR(f )] (4). We calculated ensemble averages of the power spectral densities of the stimulation command [S X ⅐ X(f )] and HR [SHR.HR(f )] and the cross spectral density between the two signals [S HR.X(f )]. Finally, we obtained the transfer function [H(f)] from the nerve stimulation to HR response using the following equation (23):
To quantify the linear dependence of the HR response to vagal or sympathetic nerve stimulation, we estimated the magnitude-squared coherence function [Coh(f)] using the following equation (23):
The coherence function ranges zero and unity and indicates a frequency-domain measure of linear dependence between input and output variables.
Because previous studies found that the transfer function from vagal stimulation to HR approximated a first-order low-pass filter with pure delay (14, 24) , we determined the parameters of the vagal transfer function using the following model:
where K is dynamic gain (in beats ⅐ min Ϫ1 ⅐ Hz Ϫ1 ), fC is the corner frequency (in Hz), and L is pure delay (in s). Variables f and j represent frequency and an imaginary unit, respectively. The minus sign in the right side of the equation corresponds to the negative HR response to vagal stimulation.
Because previous studies suggested that the transfer function from sympathetic stimulation to HR approximated a second-order low-pass filter with pure delay (14, 28), we determined the parameters of the sympathetic transfer function using the following model:
where K is dynamic gain (in beats ⅐ min Ϫ1 ⅐ Hz Ϫ1 ), fN is the natural frequency (in Hz), is the damping ratio, and L is pure delay (in s).
Because deviation of the model transfer function [Hmodel(f)] from the estimated transfer function [Hest(f)] would affect the transfer function parameters, we assessed the goodness of fit using the following equation:
where f0, m, and N represent the fundamental frequency of the Fourier transformation, a frequency index, and the number of data points used for the fitting, respectively. When H model(f) is zero for all of the frequencies, the goodness of fit is zero. When Hmodel(f) equals Hest(f) for all of the frequencies, the goodness of fit is 100%.
To facilitate intuitive understanding of the dynamic characteristics described by the transfer function (see Appendix A for details), we calculated the step response from the corresponding transfer function as follows. An impulse response of the system was calculated using the inverse Fourier transformation of the estimated transfer function. The step response was then obtained from the time integral of the impulse response. The steady-state response was calculated by averaging the last 10 s of data from the step response. The 80% rise time for the sympathetic step response or the 80% fall time for the vagal step response was estimated as the time at which the step response reached 80% of the steady-state response.
Statistics. All data are presented as means and SD values. Mean values of HR, AP, and CSNA as well as parameters of the transfer functions and step responses were compared between the control and ANG II conditions using paired t-tests. Differences were considered significant when P Ͻ 0.05 (11) .
RESULTS
Typical recordings of the vagal stimulation command, HR, and AP obtained under control and ANG II conditions are shown in Fig. 1A . The random vagal stimulation began at 60 s. The HR decreased in response to the random vagal stimulation. ANG II, which did not affect the prestimulation baseline HR, attenuated the magnitude of the vagal stimulation-induced variations in HR. ANG II increased the AP both before and during the vagal stimulation. ANG II did not change the prestimulation or poststimulation CSNA (Fig. 1B) .
As shown in Table 1 , ANG II did not affect the mean HR before stimulation of the vagal nerve, whereas it significantly increased the mean HR during the vagal stimulation period. ANG II attenuated the reduction in HR, which was calculated as the difference between the prestimulation HR and the mean HR observed during the vagal stimulation period. ANG II significantly increased the mean AP both before and during the vagal stimulation period. ANG II did not affect the mean level of pre-or poststimulation CSNA significantly. Figure 2A illustrates the averaged transfer functions from vagal stimulation to HR obtained under the control and ANG II conditions. In the gain plots, the transfer gain was relatively constant for frequencies below 0.1 Hz and decreased as the frequency increased above 0.1 Hz. ANG II decreased the transfer gain for all of the investigated frequencies, resulting in a parallel downward shift in the gain plot. In the phase plots, the phase approached Ϫ radians at 0.01 Hz and the lag became larger as the frequency increased. ANG II did not alter the phase characteristics significantly. In the coherence plots, the coherence value was close to unity in the frequency range from 0.01 to 0.8 Hz. The sharp variation around 0.6 Hz corresponds to the frequency of the artificial ventilation. Figure  2B depicts the HR step responses calculated from the corresponding transfer functions. ANG II significantly attenuated the steady-state response without affecting the response speed.
As shown in Table 2 , ANG II significantly attenuated the dynamic gain of the vagal transfer function to 76.1 Ϯ 8.5% of the control value without affecting the corner frequency or pure delay. The goodness of fit to the first-order low-pass filter did not differ between the control and ANG II conditions. In the HR step response, ANG II significantly attenuated the steadystate response without affecting the 80% fall time.
Typical recordings of the sympathetic stimulation command, HR, and AP obtained under control and ANG II conditions are shown in Fig. 3A . The random sympathetic stimulation began at 60 s. HR increased in response to random sympathetic stimulation. ANG II did not affect the prestimulation baseline HR. The magnitude of the HR variation in response to sympathetic stimulation did not change significantly. ANG II increased the AP both before and during the sympathetic stimulation. ANG II did not change the pre-or poststimulation CSNA significantly (Fig. 3B) .
As shown in Table 3 , ANG II did not affect the mean HR before or during the period of sympathetic stimulation. ANG II did not affect the increase in HR, calculated as the difference between the prestimulation HR and the mean HR in response to sympathetic stimulation. ANG II significantly increased the mean AP both before and during the sympathetic stimulation period. ANG II did not affect the mean level of pre-or poststimulation CSNA significantly. Figure 4A illustrates the averaged transfer functions from sympathetic stimulation to HR obtained under control and ANG II conditions. In the gain plots, the transfer gain decreased as the frequency increased. ANG II did not change the transfer gain markedly. In the phase plots, the phase approached zero radians at 0.01 Hz and increasingly lagged as the frequency increased. ANG II did not affect the phase characteristics significantly. The coherence value was above 0.9 for the frequency range below 0.1 Hz and decreased in the frequency range above 0.1 Hz. Figure 4B depicts the HR step responses calculated from the corresponding transfer functions. ANG II did not affect the steady-state response or the response speed. Data are means Ϯ SD values; n ϭ 7. HR, heart rate; AP, arterial pressure; CSNA, cardiac sympathetic nerve activity. ‡The difference was calculated by subtracting the prestimulation value from the value obtained during the vagal stimulation period in each animal. *P Ͻ 0.05 and †P Ͻ 0.01 based on a paired t-test. Exact P values are also shown.
As shown in Table 4 , ANG II slightly attenuated the dynamic gain of the sympathetic transfer function to 92.5 Ϯ 8.9% of the value observed under control conditions. ANG II did not affect the natural frequency, damping ratio, or pure delay. The goodness of fit to the second-order low-pass filter did not differ between the control and ANG II conditions. In the HR step response, ANG II did not affect the steady-state response or the 80% rise time. As shown in Table 5 , there were no significant differences in the parameters of the sympathetic transfer function between repeated estimations with an intervening interval of more than 20 min.
DISCUSSION
Intravenous administration of ANG II at 10 g⅐kg Ϫ1 ⅐h
Ϫ1
increased AP but did not affect mean HR or mean CSNA during prestimulation baseline conditions (Tables 1 and 3 ), suggesting that ANG II at this dose did not affect the residual sympathetic tone to the heart significantly. ANG II significantly attenuated the dynamic gain of the transfer function from vagal stimulation to HR, whereas it only slightly attenuated that of the transfer function from sympathetic stimulation to HR (Tables 2 and 4) .
Effects of ANG II on the transfer function from vagal stimulation to HR.
ANG II attenuated the dynamic gain of the transfer function from vagal stimulation to HR without affecting the corner frequency or pure delay ( Fig. 2 and Table 2 ). Several interventions can affect the dynamic gain of the vagal transfer function and significantly change the corner frequency. For example, inhibition of cholinesterase, which interferes with the rapid hydrolysis of ACh, augments the dynamic gain and decreases the corner frequency (29) . Moreover, blockade of muscarinic K ϩ channels, which interferes with fast, membrane-delimited signal transduction, has been shown to attenuate the dynamic gain and decrease the corner frequency (26). Data are means Ϯ SD values; n ϭ 7 except for CSNA data where n ϭ 5. †The difference was calculated by subtracting the prestimulation value from the value obtained during the sympathetic stimulation period in each animal. *P Ͻ 0.01 based on a paired t-test. Exact P values are also shown. On the other hand, several other interventions have been shown to alter the dynamic gain of the vagal transfer function without changing the corner frequency. Concomitant cardiac sympathetic nerve stimulation or increased intracellular cyclic AMP levels augments the dynamic gain without affecting the corner frequency (14, 27) , whereas ␤-adrenergic blockade or high plasma NE attenuates the dynamic gain without affecting the corner frequency (24, 25) . Because ␣-adrenergic blockade nullifies its effects, high plasma NE probably functions via ␣-adrenergic receptors on preganglionic and/or postganglionic vagal nerve terminals to limit ACh release during vagal stimulation (24) . Our observation that ANG II attenuated the dynamic gain without affecting the corner frequency or pure delay is similar to the results observed with high plasma NE, suggesting that ANG II limits ACh release during vagal stimulation. Although estimated values of the corner frequency ranged from 0.1 to 0.4 among studies, the difference may be attributable to the difference in the input signal properties (see Appendix B for details).
Although Andrews et al. (2) reported that ANG II (500 ng/kg, iv bolus) did not inhibit vagally induced bradycardia in anesthetized ferrets, Potter (31) demonstrated that ANG II (5-10 g, iv bolus; body weight not shown) attenuated vagally induced bradycardia in anesthetized dogs. The latter study also showed that the addition of ANG II (2-5 g/25 ml) to an organ bath attenuated vagally induced bradycardia in isolated guineapig atria. In that study, ANG II did not attenuate ACh-induced bradycardia, suggesting that the inhibition of bradycardia by ANG II was due to an inhibition of ACh release from vagal nerve terminals (31) . In a previous study, we confirmed that intravenous ANG II (10 g ⅐kg Ϫ1 ⅐h
Ϫ1
) attenuated myocardial interstitial ACh release in response to vagal nerve stimulation in anesthetized cats (17) . The site of this inhibitory action was thought to be parasympathetic ganglia rather than postganglionic vagal nerve terminals, because losartan, an antagonist of the ANG II receptor subtype 1 (AT 1 receptor), abolished the inhibitory action of ANG II when it was administered intravenously but not when it was administered locally through a dialysis fiber. ANG II may also function at the coronary endothelium and produce a diverse range of paracrine effects (6) . Although the exact mechanisms remain to be elucidated, intravenous ANG II inhibits ACh release and thereby attenuates the dynamic gain of the vagal transfer function without affecting the corner frequency or pure delay.
Although the observed attenuation of the dynamic HR response to vagal stimulation by ANG II is relatively small, it may have pathophysiological significance as follows. In a previous study, our laboratory has shown that chronic intermittent vagal stimulation significantly improved the survival of chronic heart failure rats after myocardial infarction (21) . In that study, the vagal stimulation intensity was such that it reduced HR only by 20 to 30 beats/min (5-10%) in rats. Therefore, change in the vagal effects on the heart, even if relatively small, could affect the evolution of heart failure. Increased plasma or tissue levels of ANG II in heart failure might attenuate vagal neurotransmission, contributing to the aggravation of disease states. Effects of ANG II on the transfer function from sympathetic stimulation to HR. Although ANG II attenuated the dynamic gain of the transfer function from sympathetic stimulation to HR without affecting the natural frequency, damping ratio, or pure delay, the attenuating effect was not definitive because the effect was not significant on the steady-state response in the calculated step response (Fig. 4 and Table 4 ). There are conflicting reports about the effects of ANG II on sympathetic control of the heart. Starke (33) reported that ANG II (1 ng/ml) potentiated NE release in response to postganglionic sympathetic nerve stimulation in isolated rabbit hearts, whereas no effect on spontaneous or tyramine-induced NE output was observed. Farrell et al. (10) demonstrated that administration of ANG II (100 M at 1 ml/min for 10 min; ϳ35-42 g⅐kg Ϫ1 ) into right atrial ganglionated plexus neurons via a branch of the right coronary artery caused the release of catecholamine into the myocardial interstitial fluid of anesthetized dogs, suggesting that ANG II affects intrinsic cardiac neurons. In that study, the effect of ANG II on the catecholamine release induced by cardiac sympathetic nerve stimulation was not investigated. On the other hand, Lameris et al. (19) demonstrated that administration of ANG II (0.5 ng⅐kg Ϫ1 ⅐min Ϫ1 or 30 ng⅐kg Ϫ1 ⅐h
) into the left anterior descending coronary artery of anesthetized pigs did not yield spontaneous NE release or enhance the NE release induced by cardiac sympathetic nerve stimulation. Cardiac ganglia derived from different species can demonstrate differences in phenotype for ANG II receptors, and this may impact on the resultant neurohumoral interactions. Dendorfer et al. (7) demonstrated that ANG II (0.3 to 1 g/kg bolus) increased renal sympathetic nerve activity during ganglionic blockade in pithed rats, suggesting direct ganglionic excitation by ANG II. In the present study, because we stimulated the postganglionic cardiac sympathetic nerve, possible direct ganglionic excitation by ANG II might not have affected the dynamic sympathetic control of HR. In addition, postganglionic CSNA did not change significantly in our experimental conditions (Tables 1 and 3 ), indicating that the 10 g ⅐kg Ϫ1 ⅐h Ϫ1 dose of intravenous ANG II was not high enough to produce direct ganglionic excitation.
In isolated rabbit hearts, Peach et al. (30) demonstrated that ANG II (0.2 ng/ml) inhibited NE uptake. Starke (33) reported a higher dose of ANG II (10 g/ml) to inhibit NE uptake. In a previous study from our laboratory, blockade of neuronal NE uptake using desipramine attenuated the dynamic gain, decreased the natural frequency, and increased the pure delay of the transfer function from sympathetic stimulation to HR (28) . In the present study, however, neither the natural frequency nor the pure delay was changed by ANG II, suggesting that NE uptake was not inhibited. In an in vivo study using canine hearts, Lokhandwala et al. (22) demonstrated that ANG II (100 and 200 ng⅐kg Ϫ1 ⅐ min Ϫ1 or 6 and 12 g⅐ kg Ϫ1 ⅐min Ϫ1 iv) did not affect the positive chronotropic effects of either postganglionic cardiac sympathetic nerve stimulation or intravenous NE infusion. In that study, ANG II enhanced the positive chronotropic effects of sympathetic nerve stimulation but not of intravenous NE infusion after blocking neuronal NE uptake with desipramine. The authors' interpretation of the results was that ANG II facilitated NE release in response to sympathetic nerve stimulation, whereas any effects of ANG II might be masked in animals with functioning neuronal NE uptake mechanisms (22) . To make matters more complex, Lameris et al. (19) did not observe enhanced NE release during cardiac sympathetic stimulation in porcine hearts even after neuronal NE uptake was blocked with desipramine. Thus it appears that differences in species, ANG II doses, and experimental settings (in vivo vs. isolated hearts, intravenous vs. intracoronary administration, with or without the contribution of sympathetic ganglia) critically affected the experimental results. Therefore, we believe that assessing the relative effects of ANG II on the vagal and sympathetic systems is important to understand the pathophysiological roles of ANG II in the autonomic regulation of HR.
Limitations. Our results should be interpreted in the context of various experimental limitations. First, we obtained data from anesthetized animals. If the data had been obtained under conscious conditions, the results might have been different. Because we disabled the arterial baroreflexes and cut the autonomic efferent pathways, however, the anesthetics should not have markedly affected our results. Second, because we stimulated the postganglionic cardiac sympathetic nerve, the possible effects of ANG II on the sympathetic ganglia were not assessed. Further studies that stimulate the preganglionic cardiac sympathetic nerve with various doses of ANG II are required to determine the effects of ANG II on the cardiac sympathetic ganglionic transmission. Finally, ANG II may affect the autonomic regulation of HR chronically. Further studies focused on the effects of chronically elevated ANG II levels on the autonomic regulation of HR are required to elucidate the pathophysiological significance of elevated ANG II levels.
In conclusion, continuous intravenous administration of ANG II at a dose that did not induce direct cardiac sympathetic ganglionic excitation significantly attenuated the dynamic gain of the transfer function from vagal stimulation to HR. The attenuation of the transfer gain was observed uniformly in the frequency range under study, suggesting that ANG II can attenuate the HF component of HRV even when vagal outflow from the central nervous system remains unchanged. In addition, the same dose of ANG II did not markedly affect the dynamic gain of the transfer function from postganglionic sympathetic stimulation to HR. Although there remains a room for arguments relating to the different site of stimulation (preganglionic for vagal vs. postganglionic for sympathetic), possible disproportional suppression of the dynamic vagal and sympathetic regulation of HR likely results in a relative dominance of sympathetic control in the presence of ANG II. Because many neurohumoral elements remodel or adapt during the evolution of cardiac pathology (18), we cannot directly extrapolate the results of acute neurohumoral interactions observed in the present study to the chronic pathological situations. If we do so, however, the reduction of the HF component of HRV in patients with cardiovascular diseases, such as myocardial infarction and heart failure (34), may be partly explained by the peripheral effects of ANG II on the dynamic autonomic regulation of HR.
APPENDIX A
Meaning of a step response calculated from a transfer function. We calculated a step response from a transfer function relating to the vagal or sympathetic HR control. The calculated step response is useful for time-domain interpretation of the low-pass filter characteristics described by the frequency-domain transfer function but does not necessarily conform to an experimentally estimated step response because of the following reasons. The transfer function identifies the linear input-output relationship of a given system around a mean input signal (5 Hz for vagal and 2.5 Hz for sympathetic stimulation in the present study). The step response is then calculated for a unit change in the input signal. If we perform a kind of experiment where we change the stimulation frequency from 4.5 to 5.5 Hz for the vagal system and from 2 to 3 Hz for the sympathetic system, the resultant step response is most likely close to the calculated step response. The ordinary experimental step response is, however, estimated by a step input in which the stimulation is completely turned off before the stimulation starts. The calculated step response and the ordinary experimental step response can conform only when the system is purely linear. Whenever nonlinearities exist such as threshold and saturation commonly observed in biological systems, the two step responses disagree. Conversely, information gained by the ordinary experimental step response has a limited ability to estimate the dynamic HR response unless the system is purely linear.
Once vagal or sympathetic transfer function is identified, an impulse response of the system is obtained by an inverse Fourier transform of the transfer function. We can estimate the dynamic HR response from a convolution of a input signal and the impulse response. Figure 5 represents typical data of measured HR and calculated HR based on the transfer function. Figure 5A is a continuation of the time series obtained under the control condition depicted in Fig. 1A . Figure 5B shows a scatter plot of measured HR versus calculated HR during dynamic vagal stimulation. The solid line indicates a linear regression line (r 2 ϭ 0.94). Figure 5C is a continuation of the time series obtained under the control condition depicted in Fig. 3A . Figure 5D shows the scatter plot of measured HR versus calculated HR during dynamic sympathetic stimulation. The solid line indicates a linear regression line. Although a slight convex nonlinearity is noted between the measured HR and calculated HR, squared correlation coefficient is high (r 2 ϭ 0.89). These results indicate that the transfer function can represent the dynamic HR response reasonably well.
APPENDIX B
Binary white noise versus Gaussian white noise. In a previous study from our laboratory (29), we reported a corner frequency of ϳ0.1 Hz for a transfer function from vagal stimulation to HR, which was distinctly different from the result of the present study. Possible explanation for the discrepancy is the difference in the input variance (or power) of vagal stimulation. In the previous study, we used a Gaussian white noise (GWN) with a mean stimulation frequency of 5 Hz and a SD of 2 Hz so that the input signal covered at most 98.8% (means Ϯ 2.5 SD) of the Gaussian distribution when the actual stimulation frequency was limited between 0 and 10 Hz. The variance of the GWN signal is 4 Hz 2 . In contrast, the 0 -10 Hz binary white noise used in the present study has a variance of 25 Hz 2 . Hence, the binary white noise has a merit of increasing the input variance over the GWN when the stimulation frequency is limited between 0 and 10 Hz. Increasing the input variance is effective to increase the signal-to-noise ratio in the output signal and to improve the estimation of the transfer function.
In an earlier study on the transfer function analysis, Berger et al. ( 3) demonstrated that the roll-off of the vagal transfer function was gentle (i.e., the corner frequency was high) at high mean stimulatory rates and became more abrupt (i.e., the corner frequency was lower) with lower mean stimulatory rates. Although they attributed the difference in the roll-off characteristics to the difference in mean stimulatory rates, because they set the variance of input signal at ϳ1/4 of the mean stimulatory rates, which of the mean stimulatory rates or the input variance contributed to the determination of corner frequency seems inconclusive. Because there was no significant difference in the corner frequency between the vagal transfer functions estimated by GWNs of 5 Ϯ 2 Hz and 10 Ϯ 2 Hz (means Ϯ SD) in a previous study from our laboratory (29), we speculate that the difference in the input variance rather than the mean stimulation frequency might have caused the different values of the corner frequency between the previous and the present results. This speculation requires further verification in future.
